• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Transforming Growth Factor-[beta]^sub 1^ Promoter Polymorphism C- 509T Is Associated with Asthma

Posted on: Sunday, 8 February 2004, 06:00 CST

Transforming growth factor-[beta]^sub 1^ (TGF-[beta]^sub 1^) is increased in the lungs of individuals with asthma and may modulate airway inflammation and remodeling. Some genetic studies have found that a C-to-T single-nucleotide polymorphism (C-509T) in the TGF- [beta]^sub 1^ gene promoter may be associated with altered gene expression and asthma phenotype. To build on these data, we performed a case-control association study at this locus involving 527 subjects with asthma and 170 control subjects without asthma. All individuals were white. Genotyping at 49 unlinked polymorphisms indicated that a subset of case subjects and all control subjects were well matched and without evidence of population stratification. Logistic regression was used to model the effects of age, sex, and genotype on case-control status. The diagnosis of asthma was positively associated with the T allele and TT genotype under a codominant model (odds ratio, 2.98; 95% confidence interval, 1.45 to 6.25; p = 0.003). Total serum IgE, eosinophil count, and FEV^sub 1^% predicted levels were not associated with this polymorphism. Furthermore, we show that the C-509T polymorphism alters TGF- [beta]^sub 1^ promoter-reporter activity and promoter interactions with the transcription factor Yin Yang 1. We conclude that the T allele of C-509T is associated with the diagnosis of asthma and may enhance TGF-[beta]^sub 1^ gene transcription.

Keywords: airway remodeling; genetics; population stratification; single-nucleotide polymorphism; Yin Yang 1 transcription factor

Transforming growth factor-[beta]^sub 1^ (TGF-[beta]^sub 1^) is a multifunctional cytokine that has been implicated in the pathogenesis of asthma. Levels of TGF-[beta]^sub 1^ are increased in the bronchoalveolar lavage fluid of asthmatics as compared with those of nonasthmatic individuals and levels increase after allergen challenge (1-3). TGF-[beta]^sub 1^ is expressed by airway epithelial cells, eosinophils, helper T Type 2 lymphocytes, macrophages, and fibroblasts and may be bound and stored in the subepithelial extracellular matrix of the airways (4). TGF-[beta]^sub 1^ is important in growth, development, transformation, tissue repair, fibrosis, and the modulation of inflammatory immune responses (5), but its role in asthma is unclear. Studies in rodent models of asthma indicate that TGF-[beta]^sub 1^ may have both antiinflammatory and profibrotic effects (6-8).

The expression of TGF-[beta]^sub 1^ is influenced by polymorphisms in the TGF-[beta]^sub 1^ gene, and some of these polymorphisms may be associated with asthma and other diseases (9- 12). In particular, there is a C-to-T promoter polymorphism at base pair position -509 (position relative to transcriptional start site defined in GenBank NM_000660 and NT_011109) that alters a Yin Yang 1 (YY1) transcription factor consensus binding site (-CCATCTC/ TG-) and is associated with higher circulating concentrations of TGF- [beta]^sub 1^ in plasma (9). It has been hypothesized that the T allele enhances the YY1 binding site on the TGF-[beta]^sub 1^ promoter and is responsible for increased TGF-[beta]^sub 1^ transcription (13), although this has never been demonstrated.

Pulleyn and coworkers have shown that the T allele of the C-509T single-nucleotide polymorphism (SNP) is associated with the diagnosis of asthma and asthma severity (14). However, it is not clear whether C-509T is a functional variant or is the variant responsible for the genetic association with asthma. Moreover, this genetic association has not withstood replication in all asthma case- control studies, raising questions about its veracity (15). Several candidate genes and their polymorphisms have been associated with the diagnosis of asthma in case-control studies; however, only a few of these associations have been successfully reproduced in follow- up studies (16). Population stratification, multiple comparisons, and small study populations are among the many confounding factors that may limit case-control association studies and explain inconsistencies in published results (17, 18). It is clear that replication studies with different populations are essential for validation of any asthma genetic association.

Therefore, we sought to replicate the association of the T allele of C-509T with asthma in a large, well characterized population of case subjects and control subjects that is without evidence of population stratification. Our results demonstrate a significant association of the T allele of C-509T with asthma. To determine whether altered YY1 binding might be responsible for the association, we examined the effect of C-509T on YY1 binding and promoter function. Our results demonstrate that the T allele enhances YY1 binding and TGF-[beta]^sub 1^ promoter activity. Some of the results of these studies have been previously reported in the form of an abstract (19).

METHODS

Study Populations and Population Stratification Analysis

Case DNA was obtained from 527 white patients with asthma diagnosed according to American Thoracic Society criteria (20). Control DNA from 170 white subjects without asthma was obtained from the Environmental Medicine Genome Bank (EMGB) (21). Subjects were assessed for age, sex, history of asthma or exercise-induced bronchospasm, spirometry, and total serum IgE. Both populations arc described in Table 1 and the online supplement. All DNA was purified from peripheral blood by standard techniques after subjects provided written informed consent and approval was obtained from the Brigham and Women's Hospital (Boston, MA) Institutional Review Board.

Case subjects and control subjects were well matched genetically without any evidence of population stratification, as previously described in detail (22) and in the online supplement.

TABLE 1. DESCRIPTION OF STUDY POPULATION

Genotyping

C-509T genotyping was performed by restriction fragment length polymorphism analysis as described in detail in the online supplement. Repeat genotyping was performed on 5 of every 100 samples chosen by random selection. Genotyping errors are estimated to have occurred at a frequency of less than 1%. Inconsistencies were resolved by three or more genolyping reactions.

Statistical Analysis

The primary dichotomous outcome variable of the association analyses was case or control status for asthma. The principal explanatory variable was the genotyped polymorphisms; sex and age were included as covariates in the multivariate models. Logistic regression was used to model the effects of multiple covariates and genotype on case-control status, including an investigation of the need for interaction or polynomial terms (23). C-509T genotypes were coded into three classes (CC = 0, CT = 1, TT = 2) and analyzed categorically as two binary (1, 0) dummy variables relative to the most common homozygote genotype (CC) (i.e., a codominant model). This model estimated the risk of asthma in the carriers of the C- 509T SNP.

Serum total IgE levels, eosinophil counts, and FEV^sub 1^% predicted were analyzed as continuous variables in secondary analyses. IgE levels and eosinophil counts were log transformed to approximate a normal distribution.

Hardy-Weinberg equilibrium was tested on a contingency table of observed versus predicted genotype frequencies, using a modified Markov chain random-walk algorithm (24).

S-Plus 2000 (Mathsoft, Cambridge MA), Sib-Pair version 0.99.9 (http://www2.qimr.edu.au/davidD/), Arlequin version 2.0 (http:// anthro.unige.ch/arlequin), and Idmax (http://www.well.ox.ac.uk/ asthma/ GOLD/) were used to manage and analyze the data. p Values were derived by empirical simulation when possible. Statistical significance was defined at the standard 5% level.

Cell Culture

Normal human bronchial epithelial cells were obtained from Cambrex Bio Science Walkersville (Walkersville, MD) and grown to confluence in 60-mm petri dishes in supplied medium in accordance with the manufacturer's instructions. A549 human lung carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA). A549 cells were grown in 60-mm petri dishes in Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Gaithersburg, MD) containing 10% fetal bovine serum, streptomycin (50 g/ml), and penicillin (50 IU/ml) at 37C, 5% CO2 and were passaged at confluence every 4 days.

Electrophoretic Mobility Shift Assay

Nuclear proteins were prepared as described by Dignam and coworkers and stored at -80C in small aliquots (25). In vitro binding reactions, gel electrophoresis, and autoradiography are detailed in the online supplement. Band densitometry was performed with AlphaEase 5.1 software (Alpha Innotech, San Leandro, CA). Results are expressed as means SEM and are compared by Student t- test.

Reporter Constructs and Transient Transfection Analysis

Promoter-reporter plasmids were constructed by placing a 424-bp polymerase chain reaction-generated TGF-[beta]^sub 1^ promoter fragment into the KpnI and HindIII sites of the pGL3-Basic vector (Promega, Madison, WI) by standard techniques as detailed in the online supplement. Promoter regions were completely sequenced and are identical except for C-509T.

A549 cells were transiently transfected with SuperFect transfection reagent (Qiagen Sciences\, Germantown, MD), according to the manufacturer's instructions, and incubated for 24 hours at 37C in growth medium. Luciferase assays were performed with reporter lysis buffer and assay reagent (Promega) according to the manufacturer's instructions. Luciferase data were normalized to [beta]-galactosidase activity. Three independently synthesized plasmids were compared for each allele, and data were pooled. Results are expressed as means SEM and compared by Student t- test.

RESULTS

Association Study

General characteristics. The study population consisted of 527 case subjects and 170 control subjects; its characteristics are described in Table 1. The sex and age of asthma case subjects and nonasthmatic control subjects were significantly different, reflecting the tendency of young males to enlist in the army. The total serum IgE levels were significantly increased and the FEV^sub 1^% predicted values were significantly decreased in the asthma case subjects compared with the nonasthmatic control subjects.

Primary outcomes analysis. Genotype and allele frequencies of the C-509T SNP are given in Table 2. The distribution of genotypes in the control subjects was consistent (p = 0.53) with Hardy-Weinberg equilibrium. Univariate analysis indicated that the T allele and the TT genotype were significantly more common in case subjects than in control subjects (Table 2). Logistic regression modeling including age and sex as covariates confirmed the association of the C-509T TT genotype with asthma, with an approximately threefold increase in the risk of asthma under a codominant model (odds ratio for TT versus CC genotype, 2.98; 95% confidence interval, 1.45 to 6.25; p = 0.003) (Table 2).

The results of the stratification analysis of the 49 unlinked marker SNPs relative to C-509T are shown in Figure 1 as a frequency distribution of [chi]^sup 2^ values for alleles at 49 unlinked stratification SNPs and the C-509T SNP versus asthma case-control status. For this data set, the overall stratification test statistic was set at [chi]^sup 2^^sub 49^ = 47.9, p = 0.48 (22). A close concordance was found between expected and observed [chi]^sup 2^ values across the 49 SNPs, indicating the absence of population stratification.

Secondary outcomes analysis. Bivariate analysis within the case group did not suggest any significant associations between the C- 509T genotype and total serum IgE levels (F^sub 2, 255^ = 0.33, p = 0.72), eosinophil count (F^sub 2, 519^ = 0.02, p = 0.98), or FEV^sub 1^% predicted (F^sub 2, 494^ = 1.53, p = 0.22). Multivariate analyses confirmed the lack of association between C-509T and these secondary outcomes (data not shown).

TABLE 2. UNIVARIATE AND MULTIVARIATE ANALYSIS OF C-509T ALLELIC AND GENOTYPIC FREQUENCIES BY CASE OR CONTROL STATUS

Effect of C-509T SNP on DNA-Protein Interactions and TGF- [beta]^sub 1^ Promoter Activity

DNA-protein interactions. C-509T is located in a YY1 consensus binding site on the TGF-[beta]^sub 1^ promoter and has been implicated in transcription dysregulation (13). In particular, the T allele completes the 3' end of a YY1 consensus binding site (- CCATCTC/TG-) and may increase YY1 binding affinity for the promoter and TGF-[beta]^sub 1^ transcription. Although never demonstrated, this mechanism has been proposed as an explanation for the increased levels of TGF-[beta]^sub 1^ associated with the T allele (14). To test this hypothesis and the possibility that C-509T alters the ability of other transcription factors to interact with this promoter region, we performed electrophoretic mobility shift assays (EMSAs) with a 36-bp oligodeoxynucleotide (ODN) spanning this region and nuclear extracts made from A549 cells and human bronchial epithelial cells, cell lines known to express TGF-[beta]^sub 1^ (26, 27).

In the presence of A549 nuclear extracts, four gel-shift bands (a- d) are consistently produced by radiolabeled ODNs of both alleles (Figure 2). A similar pattern was produced by human bronchial epithelial cells (data shown in Figure E1 of the online supplement). Band d was identified as YY1 by supershift analysis using antibodies to YY1, whether the C allele (Figure 2) or the T allele (data not shown) was present. Attempts to supershift bands a-c with control antibodies to SP1 and AP2 transcription factors failed (Figure 2), and the identity of these nuclear proteins remains unknown.

Figure 7. Frequency histogram of [chi]^sup 2^ values for alleles at 49 unlinked stratification single nucleotide polymorphisms (SNPs; solid bars) and the C-509T SNP versus asthma case-control status. The [chi]^sup 2^ value for each SNP was calculated from a contingency table of genotype versus case or control status. Arrow shows the location of C-509T.

Figure 2. Electrophoretic mobility shift assay with nuclear extracts (NEs) from A549 human lung carcinoma cells and oligodeoxynucleotides representing C and T alleles of TGF- [beta]^sub 1^ C-509T. Lane 1 shows a radiolabeled oligodeoxynucleotide (ODN) with the C allele without nuclear extracts. No bands are produced. Lanes 2 and 3 show four gel-shift bands (a to d) that are produced by the addition of nuclear extracts. Lane 2, containing ODN C, shows an increase in the intensity of bands a and b compared with lane 3, containing ODN T. In contrast, bands c and d are increased in lane 3, containing ODN T, compared with lane 2, containing ODN C. Band d is supershifted from lane 4 by the addition of antibodies to YY1. Addition of antibodies to SP1 and AP2 transcription factors (lanes 5-8) does not supershift any band. Unbound ODN is seen at the bottom of the gel.

Relative band densitometry measurements for all bands are shown in Figure 3. YY1 was consistently more intense with T allele ODNs than with C allele ODNs (p = 0.0002, n = 8 each, two ODN preparations for each allele). Band c was also more intense with T allele ODNs than with C allele ODNs. In contrast, bands a and b were more intense with C allele ODNs than with T allele ODNs. Similar relative intensities were found with human bronchial epithelial cell nuclear extracts (data shown in Figure E1 of the online supplement).

Figure 3. Relative densitometry measurements of bands from electrophoretic mobility shift assay (EMSA) with A549 nuclear extracts and TCF-[beta]^sub 1^ ODNs. C allele ODNs (solid bars) and T allele ODNs (open bars) are compared. Means SEM and p values of C- versus-T comparisons are shown for each band from a representative study (n = 6, with two ODN preparations for each allele). YY1 (band d) and band c are about 38 and 34% more intense, respectively, with T allele ODNs compared with C allele ODNs. In contrast, bands a and b are about 53 and 27% more intense, respectively, with C allele ODNs compared with T allele ODNs.

Figure 4. Transient transfection analysis comparing luciferase activity of promoter-reporter constructs with the C allele versus the T allele. A549 human lung carcinoma cells were transfected with 1.5 g of empty cassette (pGL3-Basic), CMV promoter control (pGL3- Control), C allele promoter-reporter plasmid (pGL3-TGF[beta]1Pro; solid bars), or T allele promoter-reporter plasmid (pGL3-TGF- [beta]1Pro; open bars) and harvested 24 hours later. All plates were cotransfected with 0.5 [beta]g of pSV-[beta]-galactosidase to normalize transfection efficiency. Overexpression studies were performed by cotransfecting with YY1 expression construct (pcDNA- YY1). Total plasmid concentration was normalized with pcDNA3.1 backbone. Each plasmid was synthesized and compared three times to mitigate effects of plasmid preparation and random point mutations on luciferase levels. Mean ratios SEM from representative study are shown, n = 3 each. (*r = 0.828, p < 0.001 for YY1 dose effect by linear regression and p < 0.001 for allele effect by factorial analysis of variance).

Transient transfection analysis. We hypothesized that YY1 is an activator of the TGF-[beta]^sub 1^ promoter and that C-509T affects TGF-[beta]^sub 1^ gene transcription by altering the affinity of YY1, and possibly other transcription factors, for the promoter. We further speculated that increased binding of YY1 conferred by the presence of the T allele of C-509T would enhance TGF-[beta]^sub 1^ promoter activity. We tested this hypothesis by transient transfection analysis of A549 cells with TGF-[beta]^sub 1^ promoter- reporter constructs and overexpression of YY1. The promoter region contained within these constructs has no known sequence variant other than C-508T. This is possible because C-508T is the SNP most proximal to the transcription initiation site. All other known SNPs in the promoter region of TGF-[beta]^sub 1^ are upstream (5') of C- 508T and were excluded from these constructs so that the data would reflect the functional impact of C-508T. Transfection of reporter constructs containing the C allele TGF-[beta]^sub 1^ promoter upstream of the luciferase cDNA increased relative luciferase activity more than 10-fold compared with that of constructs without the promoter (pGL3-Basic) (Figure 4). Cotransfection with increasing amounts of a YY1 expression construct (pcDNA-YY1) increased luciferase activity in a dose-response fashion (Figure 4). We studied the impact of C-509T on promoter function by comparing the basal activity of two constructs that were identical except for the C versus T allele at the 509 locus. We found that the presence of the T allele consistently increased luciferase activity by about 30% compared with the activity of constructs with the C allele (Figure 4). Overexpression of YY1 increased the activity of both C and T allele constructs proportionately. In contrast, YY1 overexpression did not increase pGL3-Basic luciferase expression, suggesting that YY1 is an activator of the TGF-[beta]^sub 1^ promoter. These experiments were repeated with two additional sets of independently synthesized reporter plasmids with similar results (data not shown).

DISCUSSI\ON

We conducted a case-control association study to see whether the C-509T TGF-[beta]^sub 1^ promoter SNP influences asthma susceptibility in a relatively large population of outbred while individuals. In accordance with our primary hypothesis, we found a strong positive association between the T allele and TT genotype and the diagnosis of asthma. Secondary analyses showed no association between C-509T and IgE levels, eosinophil count, or FEV^sub 1^% predicted. Furthermore, we showed for the first time that C-509T influences the affinity of the promoter for the transcription factor YY1 and other nuclear proteins. Specifically, the T allele augments YY1 binding (about 30%) and basal promoter function (about 30%) in the context of transient transfection analysis with promoter- reporter constructs. These data suggest that C-509T may be the functional variant rather than a variant in linkage disequilibrium with a functional variant. The results of our study are in general agreement with some but not all published results examining this locus in the context of asthma. Because the odds ratio of this association is relatively high for a genetically complex disease (TT versus CC genotype: odds ratio, 2.98; 95% confidence interval, 1.45 to 6.25; p = 0.003) and the C-509T SNP is relatively common in our European-American population (30% minor allele frequency), this association could signify an important and common mechanism leading to the development of asthma.

This genetic association study has the following strengths: (1) TGF-[beta]^sub 1^ has been implicated in the pathogenesis of asthma and is an excellent asthma candidate gene (4, 6-8); (2) heritability studies indicate that TGF-[beta]^sub 1^ levels are under genetic control (9, 10); (3) TGF-[beta]^sub 1^ is located on chromosome 19q, a genomic region linked to the diagnosis of asthma in some genome- wide scans, and is orthologous with a region of the mouse genome that has been linked to bronchial hyperresponsiveness in mice (16); (4) our study is a large association study involving almost 700 individuals (17); (5) a subset of asthma case subjects and all nonasthmatic control subjects has been tested for the potential confounding factor of population stratification and determined to be well matched in this regard (18, 28); (6) case subjects and control subjects were carefully assessed from the perspective of phenotype; and finally, (7) TGF-[beta]^sub 1^ polymorphisms, and the C-509T SNP in particular, have already been associated with asthma and asthma severity in smaller genetic studies (14). As false-positive results are a common problem in the literature, replication is essential for the validation of any genetic association (17). Our results once again suggest that TGF-[beta]^sub 1^ is an asthma gene and that the C-509T SNP may be the functional variant.

More than 100 SNPs and other genetic variants have been identified in genes of the TGF-[beta]^sub 1^ signaling pathway, and a few of these have been associated with disease (11). C-509T was chosen as the sole candidate SNP because previous studies suggest that it is associated with altered serum levels of TGF-[beta]^sub 1^, asthma diagnosis, asthma severity, and serum IgE levels (9, 13, 14). For example, in a study involving 84 monozygous and 86 dizygous twins, Grainger and coworkers showed that TGF-[beta]^sub 1^ levels in plasma are under genetic control (heritability estimate, 0.54) with the C-509T SNP responsible for 8.2% of the additive genetic variance (9). The T allele was associated with higher levels of TGF- [beta]^sub 1^ than was the C allele, and there was an allele dose effect with highest levels in TT individuals (7.62 ng/ml), intermediate levels in CT individuals (5.06 ng/ml), and lowest levels in CC individuals (3.83 ng/ml) (9).

In a study by Pulleyn and coworkers, 122 individuals with severe asthma (FEV^sub 1^% predicted, 63.5%), 91 individuals with mild asthma (FEV^sub 1^% predicted, 90.9%), and 122 nonasthmatic control subjects were genotyped at four SNPs in the TGF-[beta]^sub 1^ gene (14). Only C-509T was significantly (p = 0.016) stratified among with groups, with the TT genotype found in 13.9% of individuals with severe asthma, 7.7% of individuals with mild asthma, and 2.5% of control subjects. Because the differences between the mild asthma group and control group were smaller than those found between the mild asthma group and the severe asthma group, the authors concluded that C-509T may be associated with asthma severity. Although our secondary outcomes analysis showed no association between FEV^sub 1^% predicted and genotype in our asthmatics (F^sub 2, 494^ = 1.53, p = 0.22), the results of our association study are strikingly similar to the findings of Pulleyn and coworkers.

TGF-[beta]^sub 1^ is a multifunctional cytokine that is increased in the airways of individuals with asthma compared with those without asthma and is further increased in patients with status asthmaticus (1, 3, 29). The increased TGF-[beta]^sub 1^ is localized principally in the extracellular connective tissue of the subepithelial space of the airways in association with the binding proteoglycan decorin (4). Airway epithelial cells, eosinophils, T lymphocytes, fibroblasts, and macrophages express TGF-[beta]^sub 1^; however, the precise cellular source of increased TGF-[beta]^sub 1^ in the airways of individuals with asthma is unknown (2, 3). TGF- [beta]^sub 1^ is secreted as a latent complex that must be cleaved via proteases, acid, or reactive oxygen species to become active (5). Although multiple mechanisms are involved in the control TGF- [beta]^sub 1^ activity, transcriptional mechanisms are important and regulated by inflammatory cytokines, nitric oxide, and reactive oxygen species found in the airways of individuals with asthma (26). If C-509T impacts the transcription of TGF-[beta]^sub 1^ C-509T could have important effects on the activity of TGF-[beta]^sub 1^ in the airways.

There are at least two possible mechanisms by which TGF- [beta]^sub 1^ may impact the development and severity of asthma. Some studies suggest that increased TGF-[beta]^sub 1^ has a beneficial role in asthma by suppressing airway inflammation and hyperresponsiveness through the inhibition of T lymphocytes, dendritic cells, eosinophils, and mast cells. In this way, TGF- [beta]^sub 1^ may be part of a negative-feedback loop, turning off inflammation that augments its production (7). Under this paradigm, genetic variants that are associated with increased TGF-[beta]^sub 1^ activity, such as the T allele of C-509T, would be expected to be associated with decreased asthma prevalence or decreased asthma severity. Other studies suggest that TGF-[beta]^sub 1^ has harmful effects in the airways of individuals with asthma. TGF-[beta]^sub 1^ is profibrotic, and its sustained elevation may stimulate airway remodeling. Under this paradigm, genetic variants that are associated with increased TGF-[beta]^sub 1^ activity, such as the T allele of C-509T, would be expected to be associated with higher asthma prevalence or increased asthma severity. Our study found a positive association between the T allele of C-509T and asthma prevalence, supporting this later paradigm and a harmful role of TGF- [beta]^sub 1^ in asthma.

At least 20 SNPs in addition to C-509T span the promoter and coding region of the TGF-[beta]^sub 1^ gene, and there is extensive linkage disequilibrium among these SNPs (see http:// snpper.chip.org) (13). The association of C-509T with asthma might not be causal but rather the result of another polymorphism in linkage disequilibrium with C-509T. Our data suggest that C-509T per se may have a functional impact on TGF-[beta]^sub 1^ transcription. We now show that C-509T has an effect on basal promoter function in A549 cells, with the T allele increasing reporter levels by about 30% compared with those of the C allele. Luedecking and coworkers studied the TGF-[beta]^sub 1^ promoter in COS-1 cells, using similar promoter-reporter constructs, and found an approximately 24% increase in basal activity of constructs containing the T allele versus constructs with the C allele (30). Furthermore, we now show for the first time that the C allele, in comparison with the T allele, increases the EMSA band intensity of two DNA-protein complexes (bands a and b) and decreases the band intensity of two other DNA-protein complexes (bands c and d). Although the identities of these complexes remain largely unknown, the transcription factor YY1 was identified as a component of band d by supershift analysis. Other investigators have been unable to show YY1 binding to this region of the promoter for reasons that may relate to differences in EMSA binding conditions or methods used to extract nuclear proteins (14). YY1 is a ubiquitously expressed zinc finger transcription factor that may function as both an activator or repressor of gene transcription (31). Because both the YY1 affinity and promoter activity of the T allele are increased about 30% compared with the C allele, it is tempting to speculate that alterations in YY1 affinity are responsible for the association of C-509T with asthma.

In conclusion, this case-control association study suggests that the C-509T SNP of the TGF-[beta]^sub 1^ gene is an important susceptibility locus for asthma. We speculate that the T allele of C- 509T contributes to the development of asthma by increasing basal levels of TGF-[beta]^sub 1^ gene transcription in the airways of susceptible individuals by increasing YY1 affinity for the promoter.

Am J Respir Crit Care Med Vol 169. pp 214-219, 2004

Originally Published in Press as DOI: 10.1164/rccm.200307-973OC on November 3, 2003

Internet address: www.atsjournals.org

References

1. Redington AE, Madden J, Frew AJ, Djukanovic R, Roche WR, Holgate ST, Howarth PH. Transforming growth factor-[beta]^sub 1^ in asthma: measurement in bronchoalveolar lavage \fluid. Am J Respir Crit Care Med 1997;156:642-647.

2. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-associated TGF-[beta]^sub 1^ mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997;17:326-333.

3. Ohno I, Nitta Y, Yamauchi K, Hoshi H, Honma M, Woolley K, O'Byrne P, Tamura G, Jordana M, Shirato K. Transforming growth factor [beta]^sub 1^ (TGF [beta]^sub 1^) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1996;15:404-409.

4. Redington AE, Roche WR, Holgate ST, Howarth PH. Co- localization of immunoreactive transforming growth factor- [beta]^sub 1^ and decorin in bronchial biopsies from asthmatic and normal subjects. J Pathol 1998;186:410-415.

5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor [beta] in human disease. N Engl J Med 2000;342:1350-1358.

6. Hansen G, McIntire JJ, Yeung VP, Berry G, Thorbecke GJ, Chen L, DeKruyff RH, Umetsu DT. CD4^sup +^ T helper cells engineered to produce latent TGF-[beta]^sub 1^ reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000;105:61-70.

7. Nakao A. Is TGF-[beta]^sub 1^ the key to suppression of human asthma? Trends Immunol 2001;22:115-118.

8. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector- mediated gene transfer of active transforming growth factor- [beta]^sub 1^ induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-776.

9. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type [beta]^sub 1^. Hum Mol Genet 1999;8:93-97.

10. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor- [beta]^sub 1^ gene: association with transforming growth factor- [beta]^sub 1^ production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-1020.

11. Watanabe Y, Kinoshita A, Yamada T, Ohta T, Kishino T, Matsumoto N, Ishikawa M, Niikawa N, Yoshiura K. A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-[beta]^sub 1^ (TGF-[beta]^sub 1^) and its signaling pathway. J Hum Genet 2002;47:478-483.

12. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, et al. Transforming growth factor-[beta]^sub 1^ gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:431-435.

13. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-[beta] promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998;158:1958-1962.

14. Pulleyn LJ, Newton R, Adcock IM, Barnes PJ. TGF[beta]^sub 1^ allele association with asthma severity. Hum Genet 2001;109:623- 627.

15. Hakonarson H, Bjornsdottir US, Ostermann E, Arnason T, Adalsteinsdottir AE, Halapi E, Shkolny D, Kristjansson K, Gudnadottir SA, Frigge ML, et al. Allelic frequencies and patterns of single-nucleotide polymorphisms in candidate genes for asthma and atopy in Iceland. Am J Respir Crit Care Med 2001;164:2036-2044.

16. Hoffjan S, Ober C. Present status on the genetic studies of asthma. Curr Opin Immunol 2002;14:709-717.

17. Weiss ST. Association studies in asthma genetics. Am J Respir Crit Care Med 2001;164:2014-2015.

18. Silverman EK, Palmer LJ. Case-control association studies for the genetics of complex respiratory diseases. Am J Respir Cell Mol Biol 2000;22:645-648.

19. Silverman ES, Subramaniam V, Raby BA, Palmer LJ, Hallock A, Faffe DS, Shikanai T, Drazen JM, Weiss ST, Shore S. The TGFB1 C- 509T promoter polymorphism is associated with asthma [abstract]. Am J Respir Crit Care Med 2003;167:A749.

20. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.

21. Sonna L, Zhao L, Angel K, Cullivan M, Lilly C. Environmental Medicine Genome Bank: current composition. Washington, DC: U.S. Government Printing Office; 2000. USARIEM Technical Note TN00-8.

22. Baron RM, Palmer LJ, Tantisira K, Gabriel S, Sonna LA, Le L, Hallock A, Libermann TA, Drazen JM, Weiss ST, et al. DNA sequence variants in epithelium-specific ETS-2 and ETS-3 are not associated with asthma. Am J Respir Crit Care Med 2002;166:927-932.

23. McCullagh P, Nelder J. Generalized linear models. London: Chapman & Hall; 1989.

24. Guo SW, Thompson EA. Performing the exact test of Hardy- Weinberg proportion for multiple alleles. Biometrics 1992;48:361- 372.

25. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489.

26. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, Cadranel J, Baud L. Reactive oxygen and nitrogen intermediates increase transforming growth factor-[beta]^sub 1^ release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999;21:128-136.

27. Dakhama A, Kraft M, Martin RJ, Gelfand EW. Induction of RANTES and TGF-[beta]^sub 1^ in airway epithelial cells by Mycoplasma pneumoniae. Am J Respir Cell Mol Biol 2003;24:24.

28. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-228.

29. Tillie-Leblond I, Pugin J, Marquette CH, Lamblin C, Saulnier F, Brichet A, Wallaert B, Tonnel AB, Gosset P. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999;159:487-494.

30. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of genetic polymorphisms in the transforming growth factor- [beta]^sub 1^ gene and the risk of Alzheimer's disease. Hum Genet 2000;106:565-569.

31. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 1999;236:197-208.

Eric S. Silverman, Lyle J. Palmer, Venkat Subramaniam, Arlene Hallock, Sheeba Mathew, Joseph Vallone, Debora S. Faffe, Toshiki Shikanai, Benjamin A. Raby, Scott T. Weiss, and Stephanie A. Shore

Department of Environmental Health, Harvard School of Public Health; Division of Pulmonary and Critical Care Medicine and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio; Western Australian Institute for Medical Research and Centre for Medical Research, University of Western Australia, Perth, Australia

(Received in original form July 17, 2003; accepted in final form October 28, 2003)

Supported by National Institutes of Health grant HL70573.

Correspondence and requests for reprints should be addressed to Eric S. Silverman, M.D., Department of Environmental Health, Harvard School of Public Health, 667 Huntington Avenue, Boston, MA 02115. E- mail: esilverm@hsph.harvard.edu

This article has an online supplement, which is accessible from this issue's table of contents online at www.atsjournals.org

Conflict of Interest Statement: E.S.S. has no declared conflict of interest; L.J.P. has no declared conflict of interest; V.S. has no declared conflict of interest; A.H. has no declared conflict of interest; S.M. has no declared conflict of interest; J.V. has no declared conflict of interest; D.S.F. has no declared conflict of interest; T.S. has no declared conflict of interest; B.A.R. has no declared conflict of interest; S.T.W. received a grant for $900,065, Asthma Policy Modeling Study, from AstraZeneca from 1997-2003 and he was a Co-Investigator on a grant from Millennium Pharmaceuticals to pursue asthma genetics in China from 1996-2001 and received a grant from Pfizer to examine diabetes mellitus and its relationship to lung function between 2000-2003 and was a consultant for Schering- Plough and received $5,000 from 1999-2000 and has been a Co- Investigator on a grant from Boehringer Ingelheim to investigate a COPD natural history model which began in 2003 (received no funds for his involvement in this project), and has been a consultant for Variagenics on human subjects issues and received $5,000 in 2003 and has been a consultant to Genome Therapeutics in 2003 and received $1,500 and was a consultant for Merck Frost on asthma genetics in 2002 and received $2,000 and was an advisor to the TENOR Study for Genetech and has received $5,000 for 2002-2003 and grant from Glaxo- Wellcome for $500,000 for genomic equipment from 2002-2003 and was a consultant for Roche Pharmaceuticals in 2000 and received no financial remuneration for this consultancy; S.A.S. was the recipient of a $15,000 grant from Merck to study the effects of IL- 9 on airway smooth muscle.

Acknowledgment: The authors thank Drs. Jeffrey M. Drazen and Larry A. Sonna for their insightful comments and suggestions.

Copyright American Thoracic Society Jan 15, 2004

More News in this Category